An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+ - HER2- Early Breast Cancer (CAMBRIA-2) (CAMBRIA-2)
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy). The planned duration of treatment in either arm within the study will be 7 years.
Apply Now